Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.61 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191035 | 0.98 | PTGDR2 (0.61) | PTGDR2PTGDRLMNACYP1A2CYP3A4 | |
| SCHEMBL1191881 | 0.92 | PTGDR2 (0.66) | PTGDR2PTGDRLMNACYP1A2CYP3A4 | |
| SCHEMBL1786345 | 0.84 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL1191888 | 0.80 | PTGDR2 (0.69) | PTGDR2PTGDRLMNACYP1A2CYP3A4 | |
| SCHEMBL1784633 | 0.77 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL1785920 | 0.76 | PTGDR2 (0.62) | PTGDR2 | |
| SCHEMBL3395183 | 0.76 | PTGDR2 (0.68) | PTGDR2PTGDRLMNACYP1A2CYP3A4 | |
| SCHEMBL5015665 | 0.75 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL1320560 | 0.74 | LMNA (1.00) | PTGDR2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6531234 | 0.74 | PTGDR2 (1.00) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888383-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20090221578-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | disclosed |
| EP-1971574-A2 | BICYCLIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY OR ANTIALLERGIC AGENTS | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007065684-A2 | BICYCLIC HETEROYCLIC COMPOUNDS AS ANTIINFLAMMATORY OR ANTIALLERGIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221578-A1 | Organic Compounds | DRD4, RDX, DRD1 | PTGDR2 618/4885PTGDR 151/4885LMNA 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.